On Monday 28th - Wednesday 30th October the 2019 Infection Prevention and Control KSA conference will take place over three days
The conference will feature three packed days containing 32 educational sessions. An international panel of keynote speakers will present on global, regional and local national issues. You will receive the latest up to date information regarding emerging threats, industry hot topics and discuss how to prevent problems before they become unmanageable. A truly worldwide showcase of best practice.
Explore the leading edge of science, innovation and technology in the exhibit hall. Browse the exhibition, learn about scientific advances in equipment and devices brought to the Kingdom from across the globe
Connect (and reconnect) with colleagues and network with healthcare professionals from the United States, Canada, Europe and across the Middle East
Riyadh in October 2019 will witness the most illuminating and analytical 3 days of Infection Prevention and Control educational content. The prestigious Infection Prevention and Control 2019KSA conference will feature internationally and nationally acclaimed speakers, sharing global best practice and case studies. In the networking zone, exhibitors will showcase the latest technologies and services from around the world to enter the market place. Join over 1000 healthcare professionals at this must-attend event.
Riyadh in October 2019 will witness the most illuminating and analytical 3 days of Infection Prevention and Control educational content. The prestigious Infection Prevention and Control 2019KSA conference will feature internationally and nationally acclaimed speakers, sharing global best practice and case studies. In the networking zone exhibitors will showcase the latest technologies and services from around the world to enter the market place. Join over 1000 healthcare professionals at this must-attend event.
“The necessity for robust hospital and community based infection control programs around the world has become obvious for the subsistence of modern medicine. Healthcare facilities serve as a platform for the emergence of bacterial resistance and a cradle for infection transmission. This comes as no surprise, especially with overcrowded healthcare facilities and the difficulty for healthcare systems to keep up with the large demand for patient care. Antimicrobial resistance (AMR) has been in the limelight for some time now. Stronger, more resistant superbugs have emerged, such as Methicillin-resistant Staphylococcus aureus (MRSA) and Vancomycin-resistant Enterococcus (VRE). Variations in mechanisms of resistance, sprouting from the diversity and complexity of resistance genes, unclear and varied transmission patterns, and the inability to identify proper cohorting policies, is like nothing we have ever seen before. In 2014, for the first time in two decades, Ebola has caused a global threat and led to a major alert, instigating the public health community to react. The Global Health Security Agenda (GHSA) was established and the enforcement of International Health Regulations (IHR) had never been stronger. In 2012, a new corona virus emerged, the Middle East Respiratory Syndrome coronavirus (MERS CoV), here on our own Arabian Peninsula, and mobilized a vigorous movement to enhance infection control practices, not only in the Gulf Health Council (GHC) countries but around the world. Establishing and sustaining infection control programs has made it as one of the top priorities for healthcare systems worldwide.” Dr Hanan Bhalky. Gulf Council for Cooperation (Infection Control)
Surveillance, prevention and control of infection cover a broad range of processes and activities carried out by the organization’s Infection Prevention and Control Department to identify and reduce risks of acquiring and transmitting infections among patients, staff, healthcare professionals, contract workers, volunteers, students, and visitors. This function also involves links to external organization support systems to reduce the risk of infection from the environment, including food and water sources. They also coordinate all activities related to the control and prevention of healthcare-associated infections (HAIs), as well as infections brought into the hospital.
Each hospital must identify those epidemiologically important infections, infection sites and associated devices, procedures and practices that will provide the focus of efforts to prevent and to reduce the risks and incidences of HAIs. A risk-based approach uses surveillance as an important component for gathering data that will guide the risk assessment. Hospitals collect and evaluate data on the following relevant infections and sites:
a. Respiratory tract - such as the procedures and medical technology associated with intubation, mechanical ventilator support, tracheostomy, and so forth.
b. Urinary tract - such as the invasive procedures and medical technology associated with indwelling catheters, urinary drainage systems, their care, etc.
c. Intravascular invasive devices - such as the insertion and care of central venous catheters, peripheral venous lines, and so forth.
d. Surgical sites - such as the care and type of dressing and associated aseptic procedures.
e. Epidemiologically significant diseases and organisms - multidrug-resistant organisms and highly virulent infections.
f. Emerging or re-emerging infections within the community
The aspired outcomes are not limited to enhancing patient safety but to establish the wellbeing of the population as a whole; including healthcare providers, visitors and sitters, and in the larger picture to maintain Global Biosecurity. Our objectives include the following.
1. Head and lead the regional antimicrobial resistance (AMR) agenda.
2. Prevent and mitigate the risk of outbreaks in the region and its global transmission, specifically related to MERS-CoV.
3. Minimize healthcare-associated infections in patients, visitors and staff members at all levels of healthcare facilities.
4. Align and unify the surveillance practices to establish and strengthen the benchmark process for healthcare-associated infections in the region.
5. Enhance the networking process among the experts nationally and regionally and connect with global entities and experts in the field.
6. Provide a global model(s) from the region in hospital-based infection control best practices
7. Share challenges and successes in mitigating healthcare-associated infections.
An additional challenge faced in the Kingdom is MERS-CoV. From 14 February through 31 March 2019, the National IHR Focal Point of Saudi Arabia reported 22 additional cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection, including four deaths, associated with the outbreak in Wadi Aldwasir. Of the 22 cases, 19 were reported from Wadi Aldwasir city including two healthcare workers. The remaining three cases, which are epidemiologically linked to the outbreak, were healthcare workers from a hospital in Khamees Mushait city, Asir region.
Since the beginning of this outbreak in January 2019, a total of 61 MERS-CoV cases, with a case fatality ratio of 13.1% (8/61), have been reported in Wadi Aldwasir city (Data correct to May 2019). The median age of reported cases was 46 years (range 16 to 85 years). Of the 61 cases, 65% (n=46) were male, and 23% (n = 14) were health care workers.
Investigations into the source of infection of the 61 cases found that 37 were health-care acquired infections, 14 were primary cases presumed to be infected from contact with dromedary camels and the remaining (10) infections occurred among close contacts outside of health care settings. As previously reported, two human to human transmission amplification events took place at a hospital during this outbreak.
CARING FOR OUR HEALTH
Our health care system has benefited from substantive investment in recent decades. As a result, we now have 2.2 hospital beds for every 1,000 people, world class medical specialists with average life expectancy rising from 66 years to 74 years in the past three decades. We are determined to optimize and better utilize the capacity of our hospitals and health care centers, and enhance the quality of our preventive and therapeutic health care services. The public sector will focus on promoting preventive care, on reducing infectious diseases and in encouraging citizens to make use of primary care as a first step. It will deepen collaboration and integration between health and social care, as well as supporting families to provide home care when necessary for their relatives. The public sector will focus on its planning, regulatory and supervisory roles in health care. We intend to provide our health care through public corporations both to enhance its quality and to prepare for the benefits of privatization in the longer term. We will work towards developing private medical insurance to improve access to medical services and reduce waiting times for appointments with specialists and consultants. Our doctors will be given better training to improve treatment for chronic diseases such as heart disease, diabetes and cancer that threaten our nation’s health.
Speaker - Dr Mohammed Garout,
Prof. of Community Medicine & Public Health Omal Qurah University CBAHI Infection Control Specialty Team Leader
Speaker: Dr Abdulilah Hawsawi, Director - Patient Safety Center (Confirmed)
Presented by Howorth Air
Speaker: Shane Stevenson – Howorth Air Technology Ltd – Product Development & Applications Manager
Speaker:- Sally Al Zoubi, Prince Sultan Military Medical City (Confirmed)
Speaker - Dr Moqbil Al Hudaithi, Consultant Infectious Diseases, Medical Director, Alhabib Hospital, Riyadh (Confirmed)
Speaker - Mr Yahya Al Nashba
General Directorate of Infection Prevention and Control in HD Centre Program (Confirmed)
Call for Abstracts, The scientific committee at Knowlex invite the attendees of IPC2019KSA to submit abstracts in the field of infection control. Abstracts may be submitted through the form on the IPC2019KSA website only, if you submit them via email you will be directed to the form and asked to resubmit. They have to be in the poster format, in English using the UK spelling, and will be accepted based on the quality of work and anticipated interest by attendees. Abstracts must contain original material neither published nor presented elsewhere, such as in a copyrighted journal or presented at another conference. They may have been previously submitted at smaller, regional meetings, but must not have been submitted elsewhere. By submitting the abstract, the author agrees that it will be presented if accepted. The abstract cannot be altered in any manner without the written consent of all authors. The deadline for submitting an abstract is Saturday, 14th October 2019.
To submit an abstract, please go to the form on the IPC2019KSA website underneath the 'Call for Abstracts' heading. Abstracts may be rejected if the online submission procedures are not followed. The abstract author must provide valid contact information, mainly a valid email address, as our main form of communication is email. It is the author's responsibility to contact the Knowlex organising committee if they do not receive email confirmation that we have received the abstract and to share all correspondence about the abstracts to all co-authors. Please check your spam/junk mail folders to ensure emails from the Knowlex organizing committee are not being filtered out of your inbox. Incomplete applications will not be accepted. Submitters are encouraged to allow several days before the deadline to resolve questions or problems with the online submission process. When submitting an abstract, the abstract author must select the most appropriate category from the list on the submission form. The scientific committee at Knowlex have the right to change the subject if they feel it would fit better elsewhere, if this happens we will inform the author. Submitted posters are to be displayed in the poster area of the conference and there are designated times for poster viewing in the conference program. Each poster viewing session will feature different topics and the poster author is requested to be at their poster in their given time slot.
Abstracts must be formatted in Arial font size 10. Authors can include l table at 10 columns x 10 rows however the words in the table will contribute to the word count, or have the table as a picture with no contribution to the word count. Authors can include a maximum of 2 pictures/graphs. The abstract text must be no longer than 3500 characters including spaces, on A2 size poster paper in landscape orientation. You must avoid brand names, but if needed capitalize them and include a trademark symbol. Abstracts must be submitted in English with UK spelling. Authors for whom English is not the first language should have their abstracts carefully reviewed for spelling, grammar, and accuracy. Non-English expressions and taxonomic names should be written in italics, for example, in vitro, and Clostridium difficile. Systematic names should be capitalized, for example, Chlamydia. Non-systematic names, generic drug names, and diseases and viruses should be lower case, for example, chlamydia, penicillin, hepatitis. If acronyms or abbreviations are used in the abstract, they must be spelled out completely prior to use. This includes acronyms and abbreviations that may be considered common by the submitter, for example, ICU for intensive care unit. Abstracts using acronyms or abbreviations inappropriately may not be accepted for presentation at the conference. The abstract must be based on complete data, they will not be accepted if they indicate that further data will be collected and presented. The titles of abstracts should be concise and accurately describe the content of the abstract. Presenting authors must be registered for the conference before submitting an abstract. Authors submitting posters will be entered into a scholarship competition with prizes worth 500 USD. People considering submitting an abstract are encouraged to register early to take advantage of the early registration discount rate. Registration and conference information can also be accessed on the IPC2019KSA website. If the presenting author withdraws an abstract after Monday 14th October, if the abstract is not presented at the scheduled session, or if the abstract is used as an advertisement for a product or service, the author will be prohibited from submitting an abstract at the next event. Those subject to the penalty will be notified by the Knowlex staff. Those who wish to dispute their penalty must write a letter to the Knowlex office.
You should choose a search result page. You can choose the page from the Theme Options > Events > Event Search Results Page option.
New membership are not allowed.